These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Putative Inhibitors of SARS-CoV-2 Main Protease from A Library of Marine Natural Products: A Virtual Screening and Molecular Modeling Study. Gentile D; Patamia V; Scala A; Sciortino MT; Piperno A; Rescifina A Mar Drugs; 2020 Apr; 18(4):. PubMed ID: 32340389 [TBL] [Abstract][Full Text] [Related]
3. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing. Kumar Y; Singh H; Patel CN J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274 [TBL] [Abstract][Full Text] [Related]
5. Anti-HCV and anti-malaria agent, potential candidates to repurpose for coronavirus infection: Virtual screening, molecular docking, and molecular dynamics simulation study. Hosseini FS; Amanlou M Life Sci; 2020 Oct; 258():118205. PubMed ID: 32777300 [TBL] [Abstract][Full Text] [Related]
6. Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs. Li Z; Li X; Huang YY; Wu Y; Liu R; Zhou L; Lin Y; Wu D; Zhang L; Liu H; Xu X; Yu K; Zhang Y; Cui J; Zhan CG; Wang X; Luo HB Proc Natl Acad Sci U S A; 2020 Nov; 117(44):27381-27387. PubMed ID: 33051297 [TBL] [Abstract][Full Text] [Related]
7. In silico molecular docking: Evaluation of coumarin based derivatives against SARS-CoV-2. Chidambaram SK; Ali D; Alarifi S; Radhakrishnan S; Akbar I J Infect Public Health; 2020 Nov; 13(11):1671-1677. PubMed ID: 33008777 [TBL] [Abstract][Full Text] [Related]
8. In Silico Insights into the SARS CoV-2 Main Protease Suggest NADH Endogenous Defences in the Control of the Pandemic Coronavirus Infection. Martorana A; Gentile C; Lauria A Viruses; 2020 Jul; 12(8):. PubMed ID: 32722574 [TBL] [Abstract][Full Text] [Related]
9. Identification of saquinavir as a potent inhibitor of dimeric SARS-CoV2 main protease through MM/GBSA. Bello M; Martínez-Muñoz A; Balbuena-Rebolledo I J Mol Model; 2020 Nov; 26(12):340. PubMed ID: 33184722 [TBL] [Abstract][Full Text] [Related]
10. Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 M Gurung AB; Ali MA; Lee J; Farah MA; Al-Anazi KM Life Sci; 2020 Aug; 255():117831. PubMed ID: 32450166 [TBL] [Abstract][Full Text] [Related]
11. Virtual screening, ADME/Tox predictions and the drug repurposing concept for future use of old drugs against the COVID-19. Hage-Melim LIDS; Federico LB; de Oliveira NKS; Francisco VCC; Correia LC; de Lima HB; Gomes SQ; Barcelos MP; Francischini IAG; da Silva CHTP Life Sci; 2020 Sep; 256():117963. PubMed ID: 32535080 [TBL] [Abstract][Full Text] [Related]
12. Protease Inhibitory Effect of Natural Polyphenolic Compounds on SARS-CoV-2: An In Silico Study. Singh R; Gautam A; Chandel S; Ghosh A; Dey D; Roy S; Ravichandiran V; Ghosh D Molecules; 2020 Oct; 25(20):. PubMed ID: 33050360 [TBL] [Abstract][Full Text] [Related]
13. A Comprehensive Mapping of the Druggable Cavities within the SARS-CoV-2 Therapeutically Relevant Proteins by Combining Pocket and Docking Searches as Implemented in Pockets 2.0. Gervasoni S; Vistoli G; Talarico C; Manelfi C; Beccari AR; Studer G; Tauriello G; Waterhouse AM; Schwede T; Pedretti A Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708196 [TBL] [Abstract][Full Text] [Related]
14. Identification of high-affinity inhibitors of SARS-CoV-2 main protease: Towards the development of effective COVID-19 therapy. Mohammad T; Shamsi A; Anwar S; Umair M; Hussain A; Rehman MT; AlAjmi MF; Islam A; Hassan MI Virus Res; 2020 Oct; 288():198102. PubMed ID: 32717346 [TBL] [Abstract][Full Text] [Related]
15. High Throughput Virtual Screening to Discover Inhibitors of the Main Protease of the Coronavirus SARS-CoV-2. Olubiyi OO; Olagunju M; Keutmann M; Loschwitz J; Strodel B Molecules; 2020 Jul; 25(14):. PubMed ID: 32668701 [TBL] [Abstract][Full Text] [Related]
16. Identification of potential inhibitors against SARS-CoV-2 by targeting proteins responsible for envelope formation and virion assembly using docking based virtual screening, and pharmacokinetics approaches. Bhowmik D; Nandi R; Jagadeesan R; Kumar N; Prakash A; Kumar D Infect Genet Evol; 2020 Oct; 84():104451. PubMed ID: 32640381 [TBL] [Abstract][Full Text] [Related]
17. Virtual screening of approved drugs as potential SARS-CoV-2 main protease inhibitors. Jiménez-Alberto A; Ribas-Aparicio RM; Aparicio-Ozores G; Castelán-Vega JA Comput Biol Chem; 2020 Oct; 88():107325. PubMed ID: 32623357 [TBL] [Abstract][Full Text] [Related]
18. Drug Repurposing for Candidate SARS-CoV-2 Main Protease Inhibitors by a Novel Sencanski M; Perovic V; Pajovic SB; Adzic M; Paessler S; Glisic S Molecules; 2020 Aug; 25(17):. PubMed ID: 32842509 [TBL] [Abstract][Full Text] [Related]
19. Computational insights into tetracyclines as inhibitors against SARS-CoV-2 M Bharadwaj S; Lee KE; Dwivedi VD; Kang SG Life Sci; 2020 Sep; 257():118080. PubMed ID: 32653520 [TBL] [Abstract][Full Text] [Related]
20. Potential anti-SARS-CoV-2 drug candidates identified through virtual screening of the ChEMBL database for compounds that target the main coronavirus protease. Tsuji M FEBS Open Bio; 2020 Jun; 10(6):995-1004. PubMed ID: 32374074 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]